Literature DB >> 26504422

Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus.

Nihat Aksakal1, Candaş Erçetin2, Beyza Özçınar1, Ferihan Aral3, Yeşim Erbil1.   

Abstract

Lithium-associated hyperparathyroidism is the leading cause of hypercalcemia in lithium-treated patients. Lithium may lead to exacerbation of pre-existing primary hyperparathyroidism or cause an increased set-point of calcium for parathyroid hormone suppression, leading to parathyroid hyperplasia. Lithium may cause renal tubular concentration defects directly by the development of nephrogenic diabetes insipidus or indirectly by the effects of hypercalcemia. In this study, we present a female patient on long-term lithium treatment who was evaluated for hypercalcemia. Preoperative imaging studies indicated parathyroid adenoma and multinodular goiter. Parathyroidectomy and thyroidectomy were planned. During the postoperative course, prolonged intubation was necessary because of agitation and delirium. During this period, polyuria, severe dehydration, and hypernatremia developed, which responded to controlled hypotonic fluid infusions and was unresponsive to parenteral desmopressin. A diagnosis of nephrogenic diabetes insipidus was apparent. A parathyroid adenoma and multifocal papillary thyroid cancer were detected on histopathological examination. It was thought that nephrogenic diabetes insipidus was masked by hypercalcemia preoperatively. A patient on lithium treatment should be carefully followed up during or after surgery to prevent life-threatening complications of previously unrecognized nephrogenic diabetes insipidus, and the possibility of renal concentrating defects on long-term lithium use should be sought, particularly in patients with impaired consciousness.

Entities:  

Keywords:  Lithium; hyperparathyroidism; nephrogenic diabetes insipidus

Year:  2015        PMID: 26504422      PMCID: PMC4605114          DOI: 10.5152/UCD.2014.2859

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  10 in total

1.  Severe hypernatraemia due to nephrogenic diabetes insipidus - a life-threatening side effect of chronic lithium therapy.

Authors:  L Sze; B Ulrich; M Brändle
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-11       Impact factor: 2.949

2.  AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.

Authors:  Weidong Wang; Chunling Li; Tae-Hwan Kwon; Mark A Knepper; Jørgen Frøkiaer; Søren Nielsen
Journal:  Am J Physiol Renal Physiol       Date:  2002-07-30

Review 3.  50 Years with lithium treatment in affective disorders: present problems and priorities.

Authors:  P Vestergaard; R W Licht
Journal:  World J Biol Psychiatry       Date:  2001-01       Impact factor: 4.132

4.  Lithium-induced nephropathy: Rate of progression and prognostic factors.

Authors:  Claire Presne; Fadi Fakhouri; Laure-Hélène Noël; Bénédicte Stengel; Christian Even; Henri Kreis; Françoise Mignon; Jean-Pierre Grünfeld
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

Review 5.  Lithium and thyroid.

Authors:  John H Lazarus
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

6.  Hypercalcemia and diabetes insipidus in a patient previously treated with lithium.

Authors:  Walid Khairallah; Ahmad Fawaz; Edward M Brown; Ghada El-Hajj Fuleihan
Journal:  Nat Clin Pract Nephrol       Date:  2007-07

7.  Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride.

Authors:  Jennifer J Bedford; Susan Weggery; Gaye Ellis; Fiona J McDonald; Peter R Joyce; John P Leader; Robert J Walker
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 8.237

8.  Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism.

Authors:  Neşe Ozbey; Yeşim Erbil; Evin Ademoğlu; Selçuk Ozarmağan; Umut Barbaros; Alp Bozbora
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

9.  Late onset nephrogenic diabetes insipidus following cessation of lithium therapy.

Authors:  H Paw; M E Slingo; M Tinker
Journal:  Anaesth Intensive Care       Date:  2007-04       Impact factor: 1.669

Review 10.  Lithium-associated hyperparathyroidism: report of four cases and review of the literature.

Authors:  Auryan Szalat; Haggi Mazeh; Herbert R Freund
Journal:  Eur J Endocrinol       Date:  2008-11-10       Impact factor: 6.664

  10 in total
  2 in total

1.  Lithium-Induced Hyperparathyroidism: An Ill-defined Territory.

Authors:  Vishwanath Pattan; Balwinder Singh; Sahar S Abdelmoneim; Chaitra Gopinath; Vishnu Sundaresh
Journal:  Psychopharmacol Bull       Date:  2021-06-01

2.  Atorvastatin lowers serum calcium levels in lithium-users: results from a randomized controlled trial.

Authors:  Jocelyn Fotso Soh; Katie Bodenstein; Harmehr Sekhon; Soham Rej; Oriana Hoi Yun Yu; Outi Linnaranta; Suzane Renaud; Artin Mahdanian; Chien-Lin Su; Istvan Mucsi; Benoit Mulsant; Nathan Herrmann; Tarek Rajji; Serge Beaulieu
Journal:  BMC Endocr Disord       Date:  2022-09-24       Impact factor: 3.263

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.